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ABSTRACT
 
Cell death characterization is becoming an integral part in toxicological studies. Mechanistic 
studies of nitro-PAHs (polycyclic aromatic hydrocarbons) of interest might help elucidate 
which chemical characteristics are most important in eliciting toxic effects. The nitroarene 
fraction of MW 247 in diesel exhaust which comprises Nitropyrene (NP) and 
Nitrofluoranthene (NF) isomers is of particular interest due to the fact that about 10% of 
direct mutagenicity is associated with this fraction.  
 
In the present study, we observed that involvement of cyp1a1 as well as intracellular 
accumulation of lipids is common to 1-NP and 3-NF cytotoxicity. We found that 1-NP and 3-
NF, cause single strand DNA breaks as well as oxidative DNA damage in Hepa1c1c7 cells 
and the damages are recognized by ATR-CHK1 pathway and p53, which appear to initiate 
diverse signalling pathways of physiological relevance reflected in different morphological 
features. 1-NP- and 3-NF-exposed Hepa1c1c7 cells exhibited marked changes in cellular 
morphology, decreased proliferation and different forms of cell death. Upon exposure to 1-NP 
or 3-NF for 24 h, both typical apoptotic and necrotic cells were observed. However, with 3-
NF in particular a large number of the cells exhibited a characteristic partial nuclear 
chromatin condensation. The caspase inhibitor Z-VAD-FMK inhibited only the apoptotic cell 
death. Nec-1 (an inhibitor of RIP-1-dependent necroptotic cell death) exhibited no inhibitory 
effects on either cell death or vacuolization in 1-NP-exposed cells, but reduced 3-NF-induced 
cell death. Additionally, cycloheximide completely attenuated 1-NP- and 3-NF-induced cell 
death. Flow cytometric analyses indicated that caspase-3 was activated differentially in the 
cell populations after exposure to 1-NP or 3-NF and TUNEL assays showed comparable 
patterns, with one population described as classic apoptotic cells. Mitochondrial release and 
translocation of LEI-DNase II, AIF and EndoG to the nucleus appear to be involved in the cell 
death processes, particularly that of 3-NF. Furthermore, Nec-1 appears to block the 
mitochondrial release of AIF and EndoG and thereby prevents membrane damage and 
eventually cell death, suggesting involvement of RIP-1 in 3-NF- induced necroptotic cell 
death. In contrast, the corresponding amine forms (1-aminopyrene and 3-aminofluoranthene) 
elicited only minor apoptotic and necrotic cell death, and cells with characteristics typical of 
either paraptosis or necroptosis were absent. 
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 All the MAPKs; ERK1/2, p38 and JNK, appear to be involved in the death process since 
marked activations were observed upon 1-NP or 3-NF exposure, and their inhibitors partly 
reduced the induced cell death. Electron microscopic examination revealed that the 
characteristic vacuolization exclusive in 1-NP-exposed cells was due to swelling of 
mitochondria, autophagosomes and endoplasmic reticulum (ER). Myelinosomes, increases in 
number as well as size of lysosomes were observed in 3-NF-exposed cells. Interestingly, 
reactive oxygen species (ROS) and ionic imbalance, typical of paraptosis, appear to be 
prominent mechanistic factors in 1-NP-induced cell death, but not 3-NF. Taken together, 1-
NP and 3-NF elicit apoptotic and non-apoptotic forms of programmed cell death (PCD), 
which are physiologically relevant processes in normal and pathological conditions. Closer 
insight into interactions between the different death pathways may be of importance in risk 
assessment and could additionally lead to novel drug discovery targets. 
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ABBREVIATIONS
3-AF, 3-aminofluoranthene  
1-AP, 1-aminopyrene  
AIF, apoptosis inducing factor  
ATM, ataxia telangiectasia mutated  
ATR, ATM- and Rad3-related  
B[a]P, benzo[a]pyrene  
BKC, big potassium channels 
BNIP3, BCL2/adenovirus E1B 19kDa interacting protein 3 
Cdk, cyclin-dependent kinases 
cyp, cytochrome P450  
EndoG, endonuclease G 
ER, endoplasmic reticulum 
ERK, extracellular signal-related kinase  
fpg, formamidopyrimidine-DNA glycosylase  
gamma-H2AX, phosphorylated H2AX 
IBT, iberiotoxin 
JNK, c-jun N-terminal kinase  
LEI-DNase, Leucocyte elastase inhibitor-DNase 
LD, lipid droplet 
MAPKs, mitogen activated protein kinases  
MC, mitotic catastrophe 
MMP, mitochondrial membrane permeabilization 
Nec-1, Necrostatin-1  
3-NF, 3-nitrofluoranthene  
Nitro-PAHs, nitro-polycyclic aromatic hydrocarbons  
1-NP, 1-Nitropyrene  
NOS, nitric oxide synthase 
PAHs, polycyclic aromatic hydrocarbons  
PARP, poly (ADP-ribose) polymerase  
PCD, programmed cell death 
PI, propidium iodide  
RIP, receptor interacting protein 
RNS, reactive nitrogen species 
ROS, reactive oxygen species  
TUNEL, TdT-mediated dUTP-biotin nick end labelling  
Z-VAD-FMK, N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me)fluoromethyl ketone.  
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INTRODUCTION
POLYCYCLIC AROMATIC HYDROCARBONS (PAHs) 
PAHs represent a major class of chemical carcinogens present in the environment in relation 
to production, refining and application of coal, mineral oil and oil shale [1-3]. Such sources as 
coal tar, vehicular exhaust, petroleum residues, coke oven emissions, and tobacco smoke 
condensate comprises a mixture of PAHs and heterocyclic aromatic hydrocarbons containing 
one or more nitrogen, sulphur, or oxygen atoms [1-3]. Human exposure to a variety of these 
complex mixtures have been associated with increased cancer incidence and other 
pathological conditions [1-3]. 
NITRO-PAHs
Exposure to nitro-PAHs is an environmental health concern. Nitro-PAHs can be formed as 
direct or indirect products of incomplete combustion of organic materials and have been 
found to be ubiquitous in ambient air [2,4]. Indoor air exposure from kerosene heaters and 
cooking oils has also been reported [2]. In diesel exhaust, the nitroarene fraction of MW 247 
which comprises of nitropyrene (NP) and nitrofluoranthene (NF) isomers (in particular 1-NP, 
3- and 8-NF) is of interest because about 10% of direct mutgenicity is associated with this 
fraction [2,5-7]. 
     
                                          
 
 
 
1-Nitropyrene (1-NP)                3-Nitrofluoranthene (3-NF)
                                               
 
 
1-Aminopyrene (1-AP)   3-Aminofluoranthene (3-AF)
 
 
Figure 1: Chemical structures of 1-NP, 1-AP, 3-NF and 3-AF.  
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METABOLIC ACTIVATION OF NITRO-PAHs
Both reductive and oxidative metabolism of these nitro-PAHs has been implicated in their 
ability to cause mutagenic activity and possibly carcinogenicity [2,5-12]. 1-NP undergoes 
extensive metabolism on the pyrene moiety as well as the nitro function of the molecule 
(Figure 2). 1-NP can be metabolized via cytochrome P450-mediated ring C-oxidation to 
epoxides, which may undergo subsequent rearrangement to nitropyrenols and conjugation or 
hydration to dihydrodiols [2,13]. Nitroreduction in one- or two-electron steps to form in 
sequence 1-nitroso-pyrene, N-hydroxy-1-AP and 1-AP, with or without subsequent 
acetylation also occurs [2,4,14-16]. A combination of ring oxidation and nitroreduction 
followed by acetylation also exists [2]. This complex biotransformation is reflected in the 
large variety of metabolites in plasma and tissue homogenates as well as adducts formed with 
blood proteins and DNA [2,8,17-19].                                                                                                                   
 
 
 
Figure 2: Metabolic pathway of 1-NP (Source- Kim HJ et al, Mol Cells. 2005 19 (1): 114-23) 
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Metabolism of 3-NF may follow similar patterns. Rat hepatic enzymes are known to catalyze 
both oxidative and reductive NF metabolism in vitro. Under aerobic conditions hydroxylation 
of the aromatic ring is the main pathway, whereas only reduction of the nitro group occurs 
under anaerobic conditions [20]. However, it appears that the isomeric position of the nitro 
group and the coplanar conformation with respect to the plane of aromatic rings has some 
influence on the biological activity of NFs [20]. The major adduct formed from 3-NF in vitro
is N-(deoxyguanosin-8-yl)-3-AF, in the presence of xanthine oxidase and DNA [21].  
 
CELL GROWTH AND DEATH 
 
Intracellular as well as extracellular signalling regulate cell growth and death, and the balance 
between cell division and death is crucial for development and maintenance of multi-cellular 
organisms [22,23]. Disorders in these processes can lead to fatal pathological consequences. 
DNA damage checkpoint is one of the monitoring systems that maintain genomic integrity. 
Checkpoint systems including, ataxia telangiectasia mutated (ATM)-CHK2 and ATM- and 
Rad3-related (ATR)-CHK1 signalling pathways are in place to sense DNA damage and 
execute cell cycle arrest by inhibition of the activity of cell cycle regulators. [24]. If cells with 
DNA damage are able to evade the various checkpoint mechanisms and enter mitosis, cell 
death during mitosis may be the final resort to avoid mutation [25]. This is essential for the 
maintenance of genomic stability and prevention of tumour development.  
 
Recently, it has become increasingly evident that the classic dichotomous classification of cell 
death into active apoptosis versus passive necrosis is a simplification of more complex 
processes that guard organisms against potentially harmful or unwanted cells [22,23,26-28]. 
The demise of cells by programmed cell death (PCD) is marked by well-defined 
morphological changes which until now had been synonymous to apoptosis. Apoptosis is an 
active process often characterized by cell shrinkage, nuclear and cytoplasmic condensation, 
DNA fragmentation, and formation of apoptotic bodies, generally phagocytosed by other cells 
[23,29-31]. One of the defining features of apoptosis is the sequential activation of multiple 
caspases, cysteine proteases that are involved in apoptotic cell death by a proteolytic cascade 
[30,32]. On the other hand, classic necrosis is passive and displays gross morphological and 
ultrastructural features that contrast apoptosis such as extensive cellular and organelle 
swelling, and an early disruption of cellular plasma membrane [29,33].  
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Since the precise molecular mechanisms of the different cell deaths have not been fully 
characterized, others have suggested alternative basis for their classification based on nuclear 
morphology of dying cells in an attempt to include the other indeterminate forms of PCDs  
[28,34]. Based on this general guideline, PCD can be differentiated into classic apoptosis, 
apotosis-like PCD with less compact, lumpy chromatin masses and necrosis-like PCDs 
exhibiting either complete absence of chromatin condensation or chromatin clustering leading 
to formation of loose speckles [28,34]. Notably, there have also been attempts to classify PCD 
according to cellular compartments involved in the process since nuclear morphology does 
not take into account the death signalling pathways involved [28].  
 
Autophagy is a catabolic process involving the degradation of a cell’s own components by the 
lysosomal machinery and autophagic-mediated cell death, which is often considered to be 
caspase-independent, is characterized mainly by the accumulation and subsequent degradation 
of various-sized cytoplasmic vacuoles by the cell’s lysosomal system [23,27]. Other forms of 
PCDs, termed non-apoptotic/caspase-independent/necrosis-like PCDs have been described 
[35-37]. One such PCD dubbed paraptosis is characterized by cytoplasmic vacuolation, along 
with mitochondrial and ER swelling, resistance to apoptotic inhibitors and the involvement of 
mitogen-activated protein kinase (MAPKs) [23,36,38,39]. Necroptosis is another PCD that 
shares the combined biochemical and ultrastructural features of apoptosis and necrosis, with 
the selective inhibition of receptor interacting protein 1 (RIP-1) by Nec-1 [35,37,40]. 
Although autophagy is activated and reactive oxygen species (ROS) levels may be elevated, 
they play no critical roles in necroptosis [35,41]. Despite the broad spectrum of necrosis-
initiating conditions, a growing body of evidence suggest that the execution of necrotic cell 
death may be carried out by a finite common set of mechanisms [33,34,40].  
 
The balance in lipid metabolism appears to be critical in determining the fate of a cell. Lipid 
accumulation leading to a PCD termed lipoptosis has been reported [42,43]. Anoikis is the 
apoptosis of cells that have lost contact with extracellular matrix or interact through an 
inappropriate integrin-matrix combination [44-47]. Mitotic catastrophe (MC) has been 
considered another death pathway triggered by mitotic failure caused by defective cell cycle 
checkpoints [22,48-50]. More recent evidence suggests that MC may not be a separate mode 
of cell death but rather a preceding process which can end up in either apoptosis or necrosis, 
and the final outcome is dependent on the molecular profile of the cell [48,51]. Cellular 
senescence, a phenomenon whereby normal differentiated cells lose the ability to divide may 
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also be considered as a type of death [29,52]. It is widely believed that cellular senescence 
evolved as a way to prevent the initiation and spread of cancer because somatic cells that have 
divided several times will have accumulated DNA mutations, and would thus have increased 
probability of becoming cancerous if cell division continued [28,29]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Micrographs of some types of cell death  
(Source–http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1973949, Pierre Golstein 
and Guido Kroemer, 2007) (A–I) Electron microscopy; (J–L) phase contrast. (A) Normal 
HeLa cells; (B) treated with staurosporin to induce apoptosis; or (C) treated with thapsigargin 
to induce autophagy (Galluzzi et al, 2007). (D) Apoptotic and (E) necroptotic Jurkat cells 
(Degterev et al, 2005). (F) Paraptotic 293T cells (Sperandio et al, 2000; copyright (2000) 
National Academy of Sciences, USA). (G) Necrotic and (H) autophagic iBMK cells 
(Degenhardt et al, 2006; Mathew et al, 2007). (I) Ras-expressing U251 glioblastoma cells 
showing macropinosomes (J.H. Overmeyer, A. Kaul, E.E. Johnson & W.A. Maltese, 
unpublished data). (J) Dictyostelium cells, vegetative, (K) undergoing vacuolar autophagic 
cell death, and (L) undergoing necrotic cell death (Laporte et al, 2007).
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SOME ORGANELLES INVOLVED IN CELL DEATH 
Upon activation of a death stimulus, cells have access to different death programs executed 
either by caspases or independent of caspases. The mitochondria, lysosomes and ER may play 
prominent roles in certain PCDs but can be involved in the different pathways [22,28,53]. 
Signals from the different cellular organelles have been found to be linked, acting upstream as 
well as downstream of each other [22,28,53]. 
 
The mitochondria appear to be essential for a broad spectrum of death pathways and its 
membrane permeabilization (MMP) is reported to define the point of no return in most PCD 
models [28,53]. A large number of pathways are upstream of MMP, however, they are strictly 
controlled by the Bcl-2 family members with only few exceptions [28,54]. Bax and Bak being 
the ‘multi-domain’ pro-apoptotic members are considered to be crucial pore-forming 
molecules that trigger MMP and the subsequent release of death-inducing molecules such as 
cytochrome c, apoptosis inducing factor (AIF), endonuclease G (EndoG) and leucocyte 
elastase inhibitor-DNase (LEI-DNase) from the mitochondrial intermembrane space [28,54]. 
ROS generation independent of the Bcl-2 family members is also known to trigger the loss of 
mitochondrial trans-membrane potential resulting in a PCD with features of autophagic 
degeneration [55] or necrotic cell death. 
 
In the classic apoptosis-necrosis paradigm, lysosomes were considered to be solely involved 
in necrotic and autophagic cell death through the release of unspecific enzymes [22,28]. 
Although lysosomal leakage is induced by undefined mechanisms, effector molecules 
released include ROS, cathepsins and H+ [22,28,53]. Cathepsins released from lysosomes 
function in the apoptotic pathway by causing MMP via cleavage of Bid or activation of PLA2 
and the subsequent increase in arachidonic acid [22,28,53]. Cathepsins may also cause 
caspase-independent chromatin condensation directly. Acidification of the cytosol is known to 
stabilize BNIP3, triggering autophagy or activate LEI-DNase II which can cause partial 
chromatinolysis in a caspase-independent manner [22,28,53,55]. The ER, another prominent 
sensor of cellular stress may initiate PCD by two main distinct mechanisms, the unfolded 
protein response and release of Ca2+ [22,28]. These two events eventually lead to MMP and 
may either activate the classical apoptosis pathway or other non-apoptotic death pathways 
[22,28].        
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Figure 4: Diagramatic representation of cross-talk between organelles in cell death  
(Source-[22]) 
 
PHYSIOLOGIC ROLE AND HEALTH IMPLICATIONS OF CELL 
DEATH
Ironic as it may be, death happens to be an essential part of living. Cells divide repetitively 
from conception onwards and their endless proliferation is compensated for by death. Cellular 
suicide, to the right extent, in the right cells, at the right times and places is therefore crucial 
to the development of organisms. Defects in the program or process can be disastrous leading 
to cancer, autoimmune disorders such as AIDS, viral infections, ischemic injury, myocardial 
infarction, sepsis, multiple organ dysfunction syndrome, fibrosis, artherosclerosis, birth 
defects and neurodegenerative diseases such as Alzheimer’s, stroke, Parkinson’s [22,28,29]. 
 
Generally, multiplicity or redundancy of cell death pathways may represent an adaptive 
advantage, considering the imperative need to remove damaged or abnormal cells in order to 
preserve integrity of organisms [56]. It has been shown that both apoptotic and necrotic death 
markers are concomitantly present in the same cell after cerebral ischemia, indicating the 
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simultaneous activation of different death programs [57]. This paradigm is also reflected in 
cases where cell death triggers that induce caspase-dependent apoptosis shifts to caspase-
independent death outcomes in cells with inhibition of apoptosis such as neurons, tumors or 
virally-infected cells [56]. There is accumulating evidence in vitro as well as in vivo that AIF 
can act as a safeguard death executioner in cancer cells with faulty caspase activation [58-60]. 
Interestingly, some proteins that block paraptosis may have complementary effects on 
apoptosis in development and cancer protection [61]. Consistent with this notion, AIF, 
EndoG, other endonucleases and proteases, as well as MAPKs are common mediators in the 
various death processes and as such some convergence of the pathways downstream may exist 
[39,61-63]. The dominant cell death phenotype has therefore been postulated to be determined 
by the relative speed of the available death programs. Thus, although characteristics of several 
death pathways can be displayed, only the fastest and most efficient is usually evident [64]. 
 
EXPERIMENTAL CONSIDERATIONS
THE EXPERIMENTAL SYSTEM
Preliminary studies of the nitro-PAHs in different cell types (primary rat lung epithelial T2 
and lung epithelial A549 cells), proved Hepa1c1c7 cells to be a more promising choice for the 
mechanistic studies aimed at in this work. 1-NP in particular, exhibited a characteristic 
vacuolization process only in the mouse hepatoma cell line which apparently demanded 
further investigations. More importantly, previous reports show that Hepa1c1c7 cells are 
capable of cyp1a1 induction, making them suitable for mechanistic studies on PAHs [65-67]. 
It would, however, have been very insightful to have a comparative study on the signalling 
and mechanistic differences in the different cell types, but as time would not permit that, such 
studies are considered in the future plans of this project. 
 
Although the mechanistic investigations in this study were performed at concentrations that 
may seem high when compared to environmentally-relevant concentrations, with highly 
lipophilic compounds such as 1-NP and 3-NF, a delayed absorption in the lung is known to 
result in a potentially higher dose to certain lung cells [68]. Furthermore, other routes of 
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exposure of PAHs such as dietry [69] and skin [70] have been found to profoundly contribute 
to their uptake in organisms.  
CHARACTERIZATION OF CELL DEATH 
Various techniques are available for the characterization of the different forms of cell death. 
In the present study, fluorescent microscopy employing Hoechst/PI staining has proven to be 
one of the most reliable techniques, though it is time-consuming, tedious and may be 
subjective. Flow cytometry has the advantage of being time-effective but when measured only 
at sub-G1, this method was unable to recognize the typical partial nuclear condensation 
evident in both apoptotic and non-apoptotic PCDs elicited in this system. However, 
employing apoptotic markers such as cleaved caspase-3 and TdT-mediated dUTP-biotin nick 
end labelling (TUNEL)-stained cells in combination with flow cytometric analyses as used in 
this study proves to be more efficient in determining the differences in different cell 
populations that are otherwise masked. Notably, techniques like western blotting also provide 
insightful and highly reliable information, such as cleavage of caspase-3 and its substrate, 
PARP, examined in this study. A combination of immunocytochemical and western blotting 
analyses, as used for activation of caspase-8 and its subsequent cleavage of important 
substrates like Bid and RIP-1, works very well. It is therefore important to use different 
techniques in toxicity assessments before any firm judgements are made. 
 
Cellular morphological changes alone are not enough to draw conclusions on cell death 
pathways. Cellular organelles such as mitochondria, lysosomes and ER can be involved in 
various pathways and may play prominent roles in certain PCDs. Prominent organelles 
involved in the death process may provide information for the basis of classification. 
Biochemical interactions in support of such findings are of utmost importance. Use of 
inhibitors that block certain processes such as protein synthesis (cycloheximide/actinomycin) 
[71], protease activation (pan-caspase inhibitors like Z-VAD-FMK or Z-FA-FMK, specific on 
cathepsin B) [72-74], BKC opening (Iberiotoxin) [75,76] and MAPKs activation [77] may 
give a clue. Notably, Nec-1 is claimed to selectively inhibit necroptosis via RIP-1 and is as 
such used as an operational definition of necroptosis [35,37,40]. In general, care should be 
taken in concentrations used and interpretation of results, since most inhibitors may have 
 17
unspecific effects. Ideally, other techniques such as antisense, siRNA and gene-
knockdown/knockouts may be used in addition, even though they may also have limitations.  
 
AIM OF STUDY 
Although it is well known that 1-NP and 3-NF are metabolically activated to mutagenic or 
carcinogenic compounds, less is known about their effect on cellular signalling and toxicity. 
The main objective of this work was thus to elucidate the toxic effects and mechanisms of 1-
NP, 3-NF and their corresponding amine metabolites in Hepa1c1c7 cells. Below are the 
specific goals to achieve our aim. 
 Examine the potency, characterize and compare the cell death elicited by 1-NP, 3-NF 
and their amine forms (Papers I, II and III)
 Investigate the role of metabolic activation of the nitro-PAHs and cell signalling 
pathways in the induced cell death(s)  (Paper I, II and III)
 Examine perturbations in cellular organelles elicited upon exposure to the compounds 
and their role in the induced cell death  (Paper I, II and III)
 Further characterize the induced cell death and examine the involvement of key 
factors in the cell death processes such as DNA damage, ROS, and ionic homeostasis 
(Paper III)
 
SUMMARY OF FINDINGS 
Paper I 
1-NP-exposed Hepa1c1c7 cells exhibited marked changes in cellular morphology, decreased 
proliferation and different forms of cell death. A dramatic increase in cytoplasmic 
vacuolization was observed already after 6 h of exposure and the cells started to round up at 
12 h. The rate of cell proliferation was markedly reduced at 24 h and apoptotic as well as 
propidium iodide (PI)-positive cells appeared. Electron microscopic examination revealed that 
the vacuolization was partly due to mitochondria swelling. The pan-caspase inhibitor Z-VAD-
FMK inhibited only the apoptotic cell death and Nec-1 (an inhibitor of necroptosis) exhibited 
no inhibitory effects on either cell death or vacuolization. In contrast, cycloheximide 
markedly reduced both the number of apoptotic and PI-positive cells as well as the 
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cytoplasmic vacuolization, suggesting that 1-NP induced a non-apoptotic PCD. All the 
MAPKs; ERK1/2, p38 and JNK, which are important intracellular signalling mediators appear 
to be involved in the death process, since marked activations were observed upon 1-NP 
exposure, and their inhibitors partly reduced the induced cell death. The ERK1/2 inhibitor PD 
98057 completely blocked the induced vacuolization, whereas the other MAPKs inhibitors 
(UO126, SP600125 and SB202190) only had minor effects on this process. These findings 
suggest that 1-NP may cause apoptosis and paraptosis. In contrast, the corresponding amine 
(1-AP) elicited only minor apoptotic and necrotic cell death, and cells with characteristics 
typical of paraptosis were absent. 
 
Paper II 
In this study, we show that the environmental pollutant, 3-nitrofluoranthene (3-NF) but not its 
amine form, 3-aminofluoranthene (3-AF), induces apoptosis as well as regulated necrosis with 
necroptotic features in Hepa1c1c7 cells. Upon exposure to 3-NF, both typical apoptotic and 
necrotic cells were observed. A large number of the cells exhibited a characteristic partial 
nuclear chromatin condensation. Cycloheximide completely attenuated 3-NF-induced cell 
death. Activation of caspase-8, -9, and -3 were observed. Moreover, Z-VAD-FMK decreased 
the apoptotic cells, whereas the number of propidium iodide (PI)-positive cells with partial 
chromatin condensation was reduced by Nec-1, an inhibitor of receptor interacting protein 
(RIP-1). Cyp1a1 but not nitric oxide synthase (NOS) appear to be involved in activation of 3-
NF to reactive metabolites. Increase in the number as well as size of lysosomes, 
myelinosomes, and activation of autophagy were also observed. 3-NF induced 
phosphorylation of ERK1/2, JNK and p38 MAPKs. Interestingly, while inhibitors of ERK1/2 
(PD 98057, UO126) and JNK (SP600125) reduced apoptotic as well as necrotic cell death, the 
p38 inhibitor, SB202190, reduced only the necrotic cell death. Taken together, 3-NF elicits 
both apoptosis and a caspase-independent programmed cell death (PCD) with autophagic 
characteristics. Conversely, with 3-AF, no apparent cytotoxic effects besides a reduction in 
cell proliferation was observed. 
 
Paper III 
Here, we observed that 1-NP and 3-NF elicited apoptotic as well as non-apoptotic 
programmed cell deaths (PCDs) with paraptotic and necroptotic characteristics, respectively, 
in Hepa1c1c7 cells. Here, we observed intracellular accumulation of lipids in both 1-NP and 
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3-NF treated cells. 1-NP and 3-NF induced single-stranded as well as oxidative DNA-
damages which appear to correspond well with the induced cytotoxicity. The DNA damage 
activated CHK1, but not ATM-CHK2 pathway in both 1-NP- and 3-NF-induced cell deaths. 
Flow cytometric analyses showed caspase-3 was activated in some cell populations but not in 
other cell populations after exposure to 1-NP or 3-NF. This distribution pattern is reflected in 
TUNEL assays which exhibited two populations, with one population described as classic 
apoptotic cells. 1-NP treated cells exhibited a more diffuse cell population pattern. 
Translocation of mitochondrial DNA-cleaving enzymes, LEI-DNase II, AIF and EndoG to the 
nucleus suggest that these DNases are involved in the cell death processes, especially for 3-
NF. Nec-1, an inhibitor of RIP-1-dependent necroptotic cell death, reduced the induced 
mitochondrial release of AIF and EndoG by 3-NF, but not by 1-NP. Oxidative damage, big 
potassium channels (BKC) and intracellular accumulation of Ca2+, typical of paraptosis, 
appear to be prominent mechanistic mediators involved in 1-NP-induced cell death, but not 3-
NF. 
 
GENERAL DISCUSSION
The ubiquitous nature of PAHs poses an environmental and occupational health concern to 
their exposure. Traffic is an important source of PAHs in urban areas and traffic-related 
pollutants seems to be implicated in the observed associations between air pollution and 
adverse health effects [2]. PAHs and nitro-PAHs are metabolized by a variety of xenobiotic-
metabolizing enzymes [3,38,65,66,78,79]. In diesel exhaust particles (DEP), in particular, 
PAHs and nitro-PAHs form part of the organic component responsible for DEP induction of 
cytochrome P450 family enzymes, among others, which are critical for their metabolism in 
the lung as well as the liver [80,81]. Consistent with these findings, we observed marked 
inductions of cyp1a1 for all PAHs tested in this study and previous ones (Paper I and II,
[65,66]). The Cyp inhibitor, -naphthoflavone, markedly blocked 1-NP- and 3-NF-induced 
cell death (Paper I and II), which is indicative of the fact that their activation to metabolites 
toxic to cells involves cyp1a1. Neither NOS nor NQO1 appeared to be involved in this 
activation process in our cell model (Paper I and II).  
 
Reactive intermediates resulting from the metabolic activation of PAHs have the ability to 
bind DNA and other macromolecules resulting in adduct formation [1,2,4,7,81-86]. In 
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general, oxidation of PAHs by Cyp enzymes is known to be the common initial step in the 
activation process that results in the production of polar biochemically reactive metabolites 
that are capable of interacting with cellular macromolecules such as DNA and proteins [3,87]. 
Electrophilic nitrenium ions generated from nitroreduction of nitro-PAHs, including 1-NP and 
3-NF, are also capable of interacting with DNA [21,88]. Both 1-NP and 3-NF have been 
reported to be genotoxic and carcinogenic in different systems [1,2,89]. In the present study, 
the intensity of DNA damage caused by the individual compounds correlated well with the 
observed cytotoxicity, suggesting that DNA damage is an important part of triggering factors 
in the observed cell death (Paper III). The nitro-PAHs were more cytotoxic and exhibited 
more genotoxicity, by way of single-stranded DNA breaks as well as oxidative DNA damage 
as opposed to their amine forms (unpublished data). 3-NF gave the highest score in single-
stranded DNA damage and is the most cytotoxic. Formation of 8-oxo-7,8-dihydro-2’-
guanosine (8-oxo-dG) is reported to be a relevant indicator of oxidative base damage that may 
lead to DNA dysregulation [90]. Interestingly, significant levels of oxidative DNA damage 
were observed only in 1-NP-exposed cells as judged by 8-oxo-dG formation (Paper III). 3-NF 
did not elicit a significant increase in oxidative DNA damage. 1-NP was also found to cause 
lipid peroxidation (Paper III). A possible role of ROS is further supported by the fact that 
thiourea partially blocked 1-NP-induced cell death, but had no significant effect on 3-NF-
induced cell death (Paper III). These findings are in line with previous reports implicating 
ROS in paraptotic cell death [76]. Although, ROS levels may be elevated in necroptotic 
signalling, it has been found to play no functional role in the death process [41].  
 
In response to genotoxic stress, ataxia telangiectasia mutated (ATM) and ATM- and Rad3-
related (ATR) become activated and sequentially activate CHK2 and CHK1, respectively 
[29]. Several checkpoints are thus activated to delay cell cycle progression and coordinate 
repair [25,29,48,49]. Cells in different cell cycle phases happen to use diverse mechanisms to 
arrest their progression. Mitotic catastrophe (MC) is used to describe dysregulated or failed 
mitosis usually as a response of mammalian cells to mitotic DNA damage [25,29,48,49]. In 
G1, DNA damage activates p53, which sequentially activates a Cdk inhibitor, p21Cip1 
[25,48]. Thus, p53 mutant tumours that are resistant to genotoxic damage are known to 
exhibit mitotic death as a delayed response [48]. In the present study, flow cytometry analyses 
showed marked increase in phosphorylated forms of CHK1 and H2AX but not ATM and 
CHK2 in 1-NP and 3-NF-exposed cells (Paper III). Thus, with regard to these compounds 
ATR signalling is prominent in their death pathway, leading to stalled replication forks as 
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opposed to double strand (ds) breaks in DNA which are more closely related to ATM 
signalling. However, gamma-H2AX showed a dramatic increase, which could be due to 
secondary dsDNA break formation, or most probably dsDNA breaks resulting from the 
activity of AIF, EndoG and LEI-DNaseII. Additionally, cell proliferation was markedly 
inhibited after exposure of Hepa1c1c7 cells to both 1-NP and 3-NF as judged by TB exclusion 
cell counts and cloning efficiency of surviving cells (Paper I and II). Flow cytometric analyses 
revealed only a small increase of cells in S-phase. Interestingly, time-laps observations of 
cells under exposure revealed impaired cell divisions associated with mitotic catastrophe after 
1-NP exposure (unpublished data). We frequently observed that cells started the mitotic 
process but were unable to complete it normally and eventually died off. 
 
A wide variety of stimuli such as DNA damage, oxidative or nitrosative stress and ligand 
binding to cell surface death receptors can initiate apoptosis [33,91]. One of the defining 
features of apoptotic cell death pathway mechanism is the formation of multiprotein 
complexes that provide the scaffolding for the activation of initiator caspases like caspase-8 
and -9 by autoproteolytic cleavage [33]. The respective complexes are the death-induced 
signalling complex and apoptosome [33]. Eventually, activation of effector caspase-3 and the 
subsequent cleavage of PARP lead to association with caspase-activated DNase which 
executes the typical internucleosomal DNA fragmentation upon activation [92]. This 
canonical pathway of caspase activation via mitochondria, attained by way of cytochrome c 
release appears to be common with both 1-NP and 3-NF-induced apoptotic pathways (Paper I 
and II). Notably, flow cytometric analyses revealed partial to no activation of caspase-3 in 
some population of cells, suggesting an early arrested apoptotic process which shifts to 
necrotic cell death as judged by the phenotype observed especially in 3-NF-exposed cells 
(Paper III). The activation of initiator caspase-8 and its subsequent cleavage of Bid in 
particular, were more clearly evident in 3-NF cellular signalling (Paper II). Other non-
mitochondrial caspase-dependent PCDs have also been discovered [93]. The death receptor-
mediated pathway is the most studied in this group [94,95]. 
 
A caspase-independent mitochondrial pathway mediated by AIF release from the intra-
membrane mitochondria space and subsequent translocation to the nucleus has been 
characterized lately [92]. AIF is known to trigger DNA fragmentation into large fragments 
corresponding to peripheral chromatin condensation typical of apoptosis-like PCD [92]. LEI-
DNase II and EndoG have been found to function similarly in paraptotic and other PCD 
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pathways [92,96]. Flow cytometry analyses of TUNEL-stained cells, allowed as to distinguish 
two cell populations with differential DNA fragmentation, suggesting partial DNA 
fragmentation and the involvement of AIF, EndoG and LEI-DNaseII in the induced cell death 
(Paper III). A potential role of these endonucleases was further supported by 
immunocytochemical analyses showing a translocation of LEI-DNaseII, AIF and EndoG to 
the nucleus in 3-NF-exposed cells in particular (Paper III). In addition, we found that the 
translocation with AIF and EndoG is partly blocked by Nec-1, suggesting involvement of 
RIP-1 in 3-NF-induced necroptotic-like PCD. Thus the population of cells exhibiting more 
DNA damage may be classified as true apoptotic cells, whereas the other population could 
include necroptotic cells with regard to 3-NF. This correlates well with the distribution pattern 
observed with cleaved caspase-3 (Paper III), and is in accordance with previous reports in 
which necroptosis has been suggested to be a cellular back-up system where apoptosis is 
inhibited [35,40].  A cell’s commitment to die has been repeatedly suggested to switch from 
apoptosis to other PCD types whereby caspase activation cannot be obtained [97-99]. 
However, both pathways may coexist in some paradigms [Paper I and II, [92,100]. Overall, 
some commonality in initiating signals which lead to different biochemical pathways, 
effecting different ultrastructural features appear to exist in 1-NP and 3-NF-exposed 
Hepa1c1c7 cells [Paper I, II and III]. Such paraptotic or necroptotic features were neither seen 
upon exposure to the corresponding amine forms, nor the prototype PAH, B[a]P. 
 
The idea that apoptosis can be initiated by caspase-independent processes had been previously 
challenged by the difficulty in outlining complete pathways in which the molecular actors are 
defined [53,101]. Lysosomes may function as death signal integrators in several apoptotic 
pathways [33,34,53,102,103]. Lysosomal cathepsins are known to translocate from the 
lysosomal lumen to the cytosol in response to p53 activation, oxidative stress, TNF and the 
lipid second messenger, sphingosine [33,53,103,104]. The lysosomal membrane 
permeabilization and cathepsin release is reported to be a crucial step of the death cascade 
[33,53,103,104]. The early phase of commitment to apoptosis is suggested to be a caspase-
independent step, followed by a caspase-mediated degradation step [28,102]. Of note, 
lysosomal leakage inevitably leads to intracellular acidification which has many consequences 
that may contribute to PCDs. This cytosolic acidification has been shown to induce post-
translational modification of the anti-apoptotic serine protease inhibitor, LEI, resulting in its 
conversion to LEI-DNase II that mediates nuclear changes typical of apoptosis-like PCDs 
[28]. Additionally, lysosomal leakage leading to cytosolic acidification has been shown to 
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trigger JNK-mediated caspase- and Bcl-2-independent necrosis-like PCD in bladder cancer 
cells [105]. Other pathways associated with ER stress and dependence receptor-induced 
apoptosis have been reported [63,106]. Evidence suggests intracellular lipid accumulation 
leading to apoptosis [42,43]. We observed lipid droplet accumulation in both 1-NP and 3-NF-
exposed cells which may be implicated in the induced cell deaths (Paper III). This possibility 
will be elucidated in another study. Another interesting variant is the apoptosis of cells that 
lose contact with the extra-cellular matrix or interact through an inappropriate integrin-matrix 
combination [44-46]. Preliminary studies suggest that the nitroaromatic drug, nilutamide may 
cause apoptosis via this mechanism in Hepa1c1c7 cells (personal communication). 
 
Toxic insults such as DNA damage, ROS/RNS elevation or binding of inflammatory 
cytokines to their receptors on the cell surface may activate both death and survival signalling 
pathways [Paper I and II, [65,66,100]. Interplay between survival and death promoting 
complexes ensues until one finally dominates and determines the cell’s fate. RIP1 is known to 
be a crucial adaptor kinase mediating these stress-induced signalling pathways and a cell’s 
commitment to death or survival [40,100,107]. RIP1 is the first member of a family of seven, 
all of which contain a kinase domain (KD) [40,100,107]. Depending on the cellular context, 
increased RIP1 expression may lead to activation of MAPKs, NF-B, apoptosis or necrosis
[40,100,107]. An active KD allows RIP1 to autophosphorylate. Besides, RIP1 also interacts 
with a pool of adaptor proteins through its intermediate domain which leads to the recruitment 
of other kinases such as MEKK1, MEKK3 and RIP3 [108]. The activation of ERK, which 
was very marked in our study (Paper II), as well as necrotic cell death is known to depend on 
the kinase activity which is not essential for the activation of the other MAPKs or NF-B 
[100]. Notably, RIP-1 is known to be a critical substrate of caspase-8 as with Bid and other 
downstream caspases such as caspase-3 [109]. Both 3-NF and 1-NP exposures appear to 
result in RIP-1 cleavage (Paper III). The efficiency of RIP-1 cleavage is suggested to be a 
critical factor in determining the execution of cell death, apoptosis in particular, by different 
death receptors [109]. Several death receptor-induced necrotic cell deaths including 
necroptosis implicate RIP1 [40,100]. The existence of a programmed necrotic pathway 
reported by Holler et al [110] showed convincing evidence that death domain receptor-
induced necrosis of T lymphocytes required functional RIP-1. Recently, the necrostatins, Nec-
1 in particular was identified as an allosteric inhibitor of the RIP-1 kinase step in necroptotic 
pathway [40]. Thus, the involvement of RIP-1 in 3-NF-induced necroptotic-like PCD is 
suggested since Nec-1 inhibits the necroptotic features and cell death (Paper II and III). RIP1 
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integrates several different upstream signals which culminate in a limited number of cellular 
responses and abolishing its kinase function may allow interference with necrotic signalling 
pathways in certain disease states. 
 
The MAPKs are serine/threonine protein kinases which play pivotal roles in a variety of cell 
functions in many cell types [111,112]. This family of proteins shares many structural 
similarities and includes three major sub-families; the extracellular signal-regulated kinases 
(ERKs), the stress related c-Jun NH2-terminal kinases (JNKs) and p38 kinases [111,112]. 
Various biochemical and molecular processes including reactive toxic metabolites lead to 
activation of cell signalling mechanisms involving the MAPKs [39,113,114]. However, 
specificity of response is achieved by the influence on gene expression and regulation of 
downstream kinases or transcription factors [111,112]. The cellular localization of these 
transducers brings them in contact with appropriate molecular targets that alter the expression 
of genes that are involved in apoptosis, necroptosis, necrosis and paraptosis 
[39,40,100,111,112]. Taken together, the mediation of the MAPKs, particularly, ERK and 
JNK pathways in the different cell death processes suggest interplay in the death pathways 
(Papers I and II). This notion is consistent with previous studies where the different cell 
deaths have been suggested to be physiologically complementary processes 
[40,91,98,99,115]. The final outcome of MAPKs activation is very difficult to predict and is 
determined by parallel interactions with several other signaling pathways. ERK is known to 
be involved in survival signalling [77]. However, recent studies have shown that ERK may 
promote cell death as well [77,111]. Thus, some duality in the function of ERK is evident. 
The PI3K-Akt survival pathway is also activated by various intracellular and extracellular 
signals [116]. Akt kinase modulates transducers that function in apoptotic pathways upon its 
activation, leading to the ability of cells to resist death signals [29,116]. Akt signalling is 
known to induce the expression of anti-apoptotic Bcl-xl and inhibit pro-apopototic activity by 
promoting nuclear translocation of MDM2, thereby negatively regulating p53-mediated 
apoptosis [29]. These cell survival pathways are therefore crucial in tumorigenesis because 
they can suppress or cause alterations in PCDs [29,116]. Dysregulation of various signalling 
pathways associated with induction of cell proliferation, modulation of cellular differentiation 
and apoptosis has been proposed to contribute to carcinogenicity of PAHs [117].  
 
Ionic homeostasis is a major function of plasma membranes as well as intracellelular 
organelle membranes [118]. Specific balance in the major inorganic cations and anions, Ca, 
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K, Na, H, Cl, phosphate and bicarbonate is fundamental to all cells [118]. Cell-specific 
differences in the expression of membrane transport proteins and regulatory factors, which 
permits variations in the absolute rates of transmembrane flux of these ions have been 
reported [118]. One interesting study demonstrated that prolonged activation of big potassium 
channels (BKCs) in response to the respiratory burst induced by monocytes initiate paraptosis 
in selected glioma cells [76]. The characteristic swelling and cytoplasmic vacuolization as 
well as cell death were abolished by iberiotoxin, a specific BKC inhibitor [76]. Confocal 
fluorescence microscopy in the same study revealed colocalization of BKCs with the two 
targeted organelles, mitochondria and ER, implicated in parpatosis [76]. Although 
mitochondria and ER are affected in 1-NP-exposed Hepa1c1c7 cells in the present study, IBT 
was unable to visibly block the cytoplasmic vacuolization process but partially reduced cell 
death (Paper III). Calcium homeostasis is also widely appreciated as a crucial determining 
step with the onset of various types of cell death [119]. Mitochondria and ER again, are the 
key organelles involved in calcium handling [28,119]. Calcium overload happens to be a 
central feature in necrotic cell death [119].  Interestingly, cellular Ca2+ accumulation appears 
to be involved in 1-NP-induced cell death, but not 3-NF, in the Hepa1c1c7 cells.
 
Autophagy plays a central role in the maintenance of cellular homeostasis [119]. Previous 
reports have implicated autophagy as the mechanism by which several anti-cancer drugs 
induce their cytotoxic effects [29,119]. However, upon nutrient deprivation, autophagy 
operates as a survival pathway particularly in organisms [119]. This duality of roles in the 
autophagic process has led to unresolved discussions as to whether it should be considered as 
a cell survival mechanism or a form of cell death [119,120]. Although necroptotic death 
exhibits autophagic characteristics, it is considered as a downstream event and not an integral 
part of the cell death pathway [35,40]. In line with these reports we observed 
autophagosomes, lysosomal leakage as well as increased expression in the autophagic marker, 
LC3b but 3-methyladenine, an inhibitor of autophagy, did not have any effect on the induced 
cell deaths (Papers II and III). Moreover, neither cathepsin B inhibitor (benzyloxycarbonyl-
phenyl-alanyl-fluoromethylketone, Z-FA-FMK), Pepstatin A (inhibitor of cathepsin D) nor 
the calpain inhibitor (N-Acetyl-L-leucyl-L-leucyl-L-norleucinal, ALLN) had any effect on 
either 3-NF or 1-NP-induced cell death (Paper III). Consistent with the notion that though 
several features may be exhibited, only the fastest and most efficient is usually evident [64]. A 
link between autophagosomal and lysosomal systems have been implicated in PCDs [64]. 
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Interestingly, lysosomal leakage leading to intracellular acidification has also been reported to 
stabilize the autophagy-inducing Bcl-2 family member, BNIP-3 [121]. 
 
Amphiphilic compounds have been reported to consistently cause cellular accumulation of 
myelinosomes [122-124]. These compounds are known to affect lipid metabolism by direct 
interference with the action of phospholipases in the ER, lysosomes and plasma membrane 
[122-124], or intercalation into the phospholipid portion of cytoplasmic membranes, 
stabilizing these lipids and eventually prevent their catabolism [122-124]. This leads to the 
accumulation of lipids with altered physicochemical properties which are recognized by the 
cell as abnormal and concentrated in myelinosomes or autophagic vesicles [122-124]. This 
mode of action might be one of the mechanisms by which 3-NF causes cytotoxicity in 
Hepa1c1c7 cells (Papers II and III). A direct link between myelinosomes, ER, and nuclear 
envelope has also been established [124]. An association between lipid and myelin 
accumulation have also been observed to have relevance in certain pathological states such as 
acute atherosis in relation to preeclampsia and a broad spectrum of pregnancy disorders [125]. 
Advances in our understanding of the molecular machinery that regulates the functional 
interaction of lipid droplets with other organelles and the cytoskeleton may have 
physiological relevance in diseases such as the Niemann-Pick type C, artherosclerosis and 
thrombosis.
 
The balance between cell growth, mitosis and cell death maintains cellular homeostasis in 
organisms [126]. Defects in genes regulating either mitosis or mitotic death may therefore 
contribute to tumorigenesis. Cell death is an intrinsic part of development, tissue homeostasis 
and immune regulation in organisms [126,127]. PCD is the predominant form of physiologic 
cell death through which organisms eliminate unwanted or damaged cells [23,29]. A wide 
range of physiological and pathological stimuli can initiate PCD by eliciting DNA or plasma 
membrane damage, receptor mechanisms and biochemical agents [23,33,91,128]. The mode 
of cell death, be it apoptotic, necrotic or indeterminate depends on the initiating stimuli and 
available cellular energy. Certain mutations allow a cell to resist death stimuli and thereby 
provide it with a selective growth advantage. Enormous mechanistic investigations 
unravelling dysregulated PCDs, apoptosis in particular, suggest that defects in the control of 
cell death or survival is implicated in pathogenesis of a wide range of diseases [29,61]. 
Deficient PCDs is associated with cancer, autoimmune disorders and viral infections among 
others, whereas excessive PCD is linked to ischemic injury, AIDS, myocardial infarction, 
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stroke, multiple organ dysfunction syndrome, and most neurodegenerative diseases 
[22,23,28,29,61].  
 
Different morphological features reflecting different biochemical pathways of physiological 
relevance are accumulating. Dysregulation of these signalling pathways associated with either 
cell growth or death has been proposed to contribute to carcinogenicity of PAHs [117,129]. A 
better understanding of mechanisms of the various PCDs and clarity in the interplay between 
apoptotic and non-apoptotic PCDs may be informative in risk assessment evaluations of toxic 
compounds and promises to be of great importance to attempts being made to treat diseases 
associated with PCDs.  
CONCLUSIONS
The work presented here has provided novel information about different cell death pathways 
induced by nitro-PAHs. A summary of conclusions drawn from these findings are listed 
below. 
  
 The nitro-PAHs appear to be more toxic than their corresponding amines and also 
cause more single-stranded as well as oxidative DNA damage, which is largely 
recognized by ATR-CHK1 genotoxic signalling pathway. 
 Both 1-NP and 3-NF induced apoptotic as well as non-apoptotic PCDs with paraptotic 
and necroptotic characteristics, respectively. 
 The activation of 1-NP and 3-NF to metabolites toxic to Hepa1c1c7 cells involves 
cyp1a1 but neither NOS nor NQO1. 
 ERK, JNK and p38 MAPKs appear to play active roles in the different cell death 
pathways elicited, consistent with the notion of interplay in these cell deaths. 
 Whereas mitochondrial and ER damage may be prominent in 1-NP-induced cell death, 
AIF, EndoG and LEI-DNase II and Nec-1-dependent signalling appear to be 
prominent mediators in 3-NF-induced cell death. 
 ROS, activation of BKCs as well as Ca2+ dysregulation are important factors that 
contribute to the cell death process induced by 1-NP, but not 3-NF.   
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FUTURE STUDIES 
 Futher clarify mechanisms of the different PCDs elicited by 1-NP and 3-NF 
employing such techniques as siRNA, antisense and gene-knockdowns
 Investigate interplays between the apoptotic and non-apoptotic PCDs by microarray or 
proteomic labelling techniques
 Comparative analyses of these nitroarenes in different cell systems, such as primary 
lung cells, hepatocytes, other cell lines and possibly in vivo studies would be 
insightful
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